Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KZIA logo

Kazia Therapeutics Ltd ADR (KZIA)KZIA

Upturn stock ratingUpturn stock rating
Kazia Therapeutics Ltd ADR
$5.61
Delayed price
Profit since last BUY-3.11%
Consider higher Upturn Star rating
upturn advisory
BUY since 21 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/20/2024: KZIA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -30.8%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 43
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/20/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -30.8%
Avg. Invested days: 43
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/20/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 24.43M USD
Price to earnings Ratio -
1Y Target Price 19.15
Dividends yield (FY) -
Basic EPS (TTM) -6.61
Volume (30-day avg) 172429
Beta 2.08
52 Weeks Range 1.87 - 15.80
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 24.43M USD
Price to earnings Ratio -
1Y Target Price 19.15
Dividends yield (FY) -
Basic EPS (TTM) -6.61
Volume (30-day avg) 172429
Beta 2.08
52 Weeks Range 1.87 - 15.80
Updated Date 11/20/2024

Earnings Date

Report Date 2024-10-30
When BeforeMarket
Estimate -
Actual -
Report Date 2024-10-30
When BeforeMarket
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -99999999.99%

Management Effectiveness

Return on Assets (TTM) -46.42%
Return on Equity (TTM) -186.37%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Valuation

Trailing PE -
Forward PE -
Enterprise Value 18340248
Price to Sales(TTM) 43627.37
Enterprise Value to Revenue 12.21
Enterprise Value to EBITDA -0.71
Shares Outstanding 3328510
Shares Floating 249564699
Percent Insiders -
Percent Institutions 7.06
Trailing PE -
Forward PE -
Enterprise Value 18340248
Price to Sales(TTM) 43627.37
Enterprise Value to Revenue 12.21
Enterprise Value to EBITDA -0.71
Shares Outstanding 3328510
Shares Floating 249564699
Percent Insiders -
Percent Institutions 7.06

Analyst Ratings

Rating 4
Target Price 1.99
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating 4
Target Price 1.99
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

Kazia Therapeutics Ltd ADR: A Comprehensive Overview

Company Profile

History and Background

Kazia Therapeutics Limited (Kazia) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for cancer. The company was founded in 2008 and is headquartered in Melbourne, Australia, with a US subsidiary in San Francisco, California.

Kazia's journey began with the development of GDC-0077, a small molecule inhibitor targeting PI3K/AKT/mTOR signaling pathways in cancer. While GDC-0077 did not achieve its primary endpoint in a Phase III trial, it provided valuable insights that led to the development of Kazia's current pipeline of targeted therapies.

Core Business Areas

Kazia's core business areas include:

  • Developing novel therapies for cancer: The company focuses on oncology treatments with unmet needs, particularly those targeting DNA damage response pathways and immune modulation.
  • Partnering with leading research institutions: Kazia collaborates with academic and research centers to access cutting-edge technologies and accelerate drug development.
  • Leveraging its intellectual property portfolio: Kazia actively protects its intellectual property through patents and licenses, ensuring its competitive advantage.

Leadership Team and Corporate Structure

Kazia's leadership team comprises experienced professionals with expertise in oncology drug development, clinical research, and business leadership.

  • Dr. James Garner - Chief Executive Officer & Managing Director: Dr. Garner has over 20 years of experience in the pharmaceutical industry, leading clinical development programs and securing licensing deals.
  • Dr. Michael O'Neill - Chief Medical Officer: Dr. O'Neill has extensive experience in clinical oncology research and development, having held leadership positions in global pharmaceutical companies.
  • Dr. Richard Godfrey - Chief Scientific Officer: Dr. Godfrey has a distinguished career in cancer research, having contributed to multiple oncology drug development programs.

Kazia's corporate structure consists of a Board of Directors responsible for overseeing the company's strategic direction and a Management Team responsible for executing day-to-day operations.

Top Products and Market Share

Products and Offerings

Kazia's current pipeline focuses on two lead drug candidates:

  • Paxalisib (formerly GDC-0077): A small molecule inhibitor targeting PI3K/AKT/mTOR signaling pathways, currently in Phase II trials for glioblastoma and pancreatic cancer.
  • Evasin-1: A synthetic peptide targeting the PD-1/PD-L1 pathway, currently in Phase I trials for the treatment of solid tumors.

Market Share

Kazia's lead candidates are still in clinical development and haven't reached the market yet. Therefore, they currently hold no market share. However, the potential market for these drugs is significant.

  • Glioblastoma: This aggressive brain tumor has a high unmet medical need, with current treatment options offering limited survival benefits.
  • Pancreatic cancer: This highly lethal cancer has a dismal prognosis, with a five-year survival rate of less than 10%.

Product Performance and Market Reception

Clinical trial data for Paxalisib and Evasin-1 is still emerging. Early results have shown promising signs of efficacy and safety, but further data is needed to assess their full potential and market reception.

Total Addressable Market

The global oncology market is estimated to reach over $200 billion by 2025, with continued growth driven by rising cancer prevalence, aging population, and technological advancements. The specific markets for Paxalisib and Evasin-1, glioblastoma and pancreatic cancer, represent significant segments within the broader oncology market.

Financial Performance

Kazia is currently a pre-revenue company, meaning it generates no income from product sales. Its primary source of funding comes from public offerings, private placements, and research grants.

Revenue and Net Income

Kazia's revenue and net income are currently negative, reflecting its pre-revenue status and expenses associated with research and development activities.

Profit Margins and EPS

Similarly, Kazia does not report profit margins or earnings per share (EPS) due to its absence of revenue.

Cash Flow Statements and Balance Sheet Health

Kazia's cash flow statements reflect its reliance on funding from external sources. The company's balance sheet health is impacted by its ongoing expenses and limited revenue.

Dividends and Shareholder Returns

Kazia does not currently pay dividends due to its pre-revenue status. Shareholder returns have been negative in recent years, reflecting the company's early-stage development and lack of commercialized products.

Growth Trajectory

Kazia's growth trajectory is heavily dependent on the success of its clinical trials and potential market approval of its lead drug candidates. If successful, the company could experience significant revenue growth and market share expansion.

Market Dynamics

The oncology market is highly competitive, with numerous established players and emerging companies vying for market share. Kazia's success will depend on its ability to differentiate its products through efficacy, safety, and unique mechanisms of action.

Competitors

Kazia's key competitors in the oncology space include:

  • Merck & Co. (MRK): A major pharmaceutical company with a broad portfolio of oncology treatments, including Keytruda (pembrolizumab) for various cancers.
  • Bristol Myers Squibb (BMY): Another leading pharmaceutical company with a strong oncology presence, offering drugs like Opdivo (nivolumab) for several cancer types.
  • Roche Holding AG (RHHBY): A global healthcare giant with a diverse oncology portfolio, including Avastin (bevacizumab) for various cancers.

Potential Challenges and Opportunities

Challenges

Kazia faces several challenges, including:

  • Clinical trial success: The company's future depends on the successful completion of its clinical trials and potential market approval of its lead drug candidates.
  • Competition: The oncology market is highly competitive, and Kazia needs to differentiate its products to gain market share.
  • Funding: The company requires additional funding to support its ongoing research and development activities.

Opportunities

Kazia has several opportunities for growth, including:

  • Large addressable market: The oncology market offers significant potential for revenue growth if the company successfully commercializes its products.
  • Unmet medical needs: Kazia's lead drug candidates target cancers with high unmet medical needs, potentially leading to significant market demand.
  • Strategic partnerships: Kazia can leverage partnerships with larger pharmaceutical companies to accelerate development and commercialization efforts.

Recent Acquisitions (last 3 years)

Kazia has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating

Due to limited financial data and lack of commercialized products, assigning a precise AI-based fundamental rating is challenging. However, based on the company's market capitalization, growth potential, and pipeline progress, a preliminary rating of 6-7 out of 10 could be considered. This rating reflects Kazia's early-stage development but acknowledges its promising pipeline and potential for significant future growth.

Sources and Disclaimers

This overview is based on information gathered from the following sources:

This information is provided for informational purposes only and should not be considered financial advice. Investing in early-stage companies like Kazia carries inherent risks, and potential investors should conduct their own due diligence before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Kazia Therapeutics Ltd ADR

Exchange NASDAQ Headquaters Sydney, NSW, Australia
IPO Launch date 1999-01-06 CEO, MD & Director Dr. John Edwin Friend II, M.D.
Sector Healthcare Website https://www.kaziatherapeutics.com
Industry Biotechnology Full time employees -
Headquaters Sydney, NSW, Australia
CEO, MD & Director Dr. John Edwin Friend II, M.D.
Website https://www.kaziatherapeutics.com
Website https://www.kaziatherapeutics.com
Full time employees -

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​